However, still a minority of patients show a clinical response and a large portion of patients exhibit tumor cell extrinsic acquired or adaptive resistance, even after initially effective ICB.11 Therefore, understanding the mechanism of action of PD1 checkpoint blockade is crucial to facilitate rational design of combination therapies. Here, PDCD1 is linked to neoplasm.